aTYR PHARMA INC Quarterly Nonoperating Income (Expense) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
aTYR PHARMA INC quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2018 to Q2 2024.
  • aTYR PHARMA INC Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $1.01M, a 17% decline year-over-year.
  • aTYR PHARMA INC Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.63M, a 69.9% increase year-over-year.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2023 was $4.52M, a 326% increase from 2022.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2022 was $1.06M, a 346% increase from 2021.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2021 was $238K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.63M $1.01M -$207K -17% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $4.84M $1.15M +$314K +37.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $4.52M $1.2M +$771K +181% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $3.75M $1.27M +$1.03M +415% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $2.73M $1.22M +$1.05M +646% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $1.67M $835K +$611K +273% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $1.06M $427K +$348K +441% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $713K $247K +$188K +319% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $525K $163K +$110K +208% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $415K $224K +$177K +377% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $238K $79K +$74K +1480% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $164K $59K +$147K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $17K $53K +$182K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$165K $47K +$154K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$319K $5K +$176K Oct 1, 2020 Dec 31, 2020 10-K 2023-03-14
Q3 2020 -$495K -$88K +$59K +40.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$554K -$129K +$78K +37.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$632K -$107K +$153K +58.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$785K -$171K +$188K +52.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-15
Q3 2019 -$973K -$147K +$290K +66.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$1.26M -$207K +$245K +54.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$1.51M -$260K +$187K +41.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$1.7M -$359K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-24
Q3 2018 -$437K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$452K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$447K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.